b'VA Has More Options as Treatment for Mantle Cell Lymphoma Expands RapidlySource: Exp Hematol Oncol. 2019; 8: 2. Published online 2019 Jan 30. doi: 10.1186/s40164-019-0126-0 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354396/In November 2019, after this study was published, the Food and Drug Administration granted accelerated approval to zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. 122020 COMPENDIUM OF FEDERAL MEDICINE'